Evidence map›Paper›PMID 39682748›Full record

ArticleCells2024

Novel mTORC2/HSPB4 Interaction: Role and Regulation of HSPB4 T148 Phosphorylation.

Zachary B Sluzala, Yang Shan, Lynda Elghazi, Emilio L Cárdenas, Angelina Hamati, Amanda L Garner, Patrice E Fort

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zachary B SluzalaDepartment of Ophthalmology & Visual Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-1666-9791
Yang ShanDepartment of Ophthalmology & Visual Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-0639-4501
Lynda ElghaziDepartment of Ophthalmology & Visual Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.
Emilio L CárdenasInterdepartmental Program in Medicinal Chemistry, The University of Michigan, Ann Arbor, MI 48109, USA.
Angelina HamatiDepartment of Ophthalmology & Visual Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0009-0003-7528-6963
Amanda L GarnerInterdepartmental Program in Medicinal Chemistry, The University of Michigan, Ann Arbor, MI 48109, USA.
Patrice E FortDepartment of Ophthalmology & Visual Sciences, The University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-3956-1908

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Vision Research Training Program - T32EY013934T32EY013934 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Patrice E. Fort · 2002 to 2026
$4.2M
Progressive Impact of Diabetes on Retinal Neuroprotection by ?-CrystallinsR01EY020895 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FORT, PATRICE E. · 2012 to 2019
$3.2M
Early Stage Training in the NeurosciencesT32NS076401 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Carol Fuzeti Elias, LESLIE S. SATIN · 2011 to 2026
$3.1M
Delineating the Biology of Translational Repressor 4E-BP1R01GM132342 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARNER, AMANDA · 2020 to 2023
$1.4M
Protective potential of functionally enhanced AlphaA-crystallin in neurodegenerationR01EY033527 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FORT, PATRICE E. · 2022 to 2022
$554k
NEI NIH HHS P30 EY007003NEI NIH HHS R01 EY020895NEI NIH HHS R01 EY033527NEI NIH HHS T32 EY013934NIDDK NIH HHS P30 DK020572NIGMS NIH HHS R01 GM132342NIH HHS 1P30EY007003-20A1NIH HHS 1R01EY020895-05A1NIH HHS 1R01EY033527-01A1NIH HHS 1T32EY013934-15A1NINDS NIH HHS T32 NS076401Research to Prevent Blindness unrestricted
6 · The paper itself

Abstract

HSPB4 and HSPB5 (α-crystallins) have shown increasing promise as neuroprotective agents, demonstrating several anti-apoptotic and protective roles in disorders such as multiple sclerosis and diabetic retinopathy. HSPs are highly regulated by post-translational modification, including deamidation, glycosylation, and phosphorylation. Among them, T148 phosphorylation has been shown to regulate the structural and functional characteristics of HSPB4 and underlie, in part, its neuroprotective capacity. We recently demonstrated that this phosphorylation is reduced in retinal tissues from patients with diabetic retinopathy, raising the question of its regulation during diseases. The kinase(s) responsible for regulating this phosphorylation, however, have yet to be identified. To this end, we employed a multi-tier strategy utilizing in vitro kinome profiling, bioinformatics, and chemoproteomics to predict and discover the kinases capable of phosphorylating T148. Several kinases were identified as being capable of specifically phosphorylating T148 in vitro, and further analysis highlighted mTORC2 as a particularly strong candidate. Altogether, our data demonstrate that the HSPB4-mTORC2 interaction is multi-faceted. Our data support the role of mTORC2 as a specific kinase phosphorylating HSPB4 at T148, but also provide evidence that the HSPB4 chaperone function further strengthens the interaction. This study addresses a critical gap in our understanding of the regulatory underpinnings of T148 phosphorylation-mediated neuroprotection.

Indexed as

Mechanistic Target of Rapamycin Complex 2alpha-Crystallin B ChainAnimalsHeat-Shock ProteinsHEK293 CellsHumansPhosphorylationProtein Bindingalpha-Crystallin B ChainCRYAB protein, humanHeat-Shock ProteinsMechanistic Target of Rapamycin Complex 2chaperoneHSPB4kinaseneuroprotectionphosphorylationsHSPαA-crystallin

Identifiers

PMID39682748
PMCPMC11640050

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.